Anika Therapeutics Inc. EBIT Margin

EBIT Margin of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Margin growth rates and interactive chart. Earnings before interest and taxes margin is an indicator of a company's profitability. Calculated as earnings before interest and taxes (EBIT) divided by revenue. It is useful for comparison of companies with different debt levels and tax rates. And EBIT margin gives a clear picture about the underlying profitability of a company's core operations. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes.


Highlights and Quick Summary

  • EBIT Margin for the quarter ending June 29, 2021 was 24.07% (a 555.86% increase compared to previous quarter)
  • Year-over-year quarterly EBIT Margin decreased by -196.24%
  • Annual EBIT Margin for 2020 was -21.71% (a -172.66% decrease from previous year)
  • Annual EBIT Margin for 2019 was 29.88% (a 45.05% increase from previous year)
  • Annual EBIT Margin for 2018 was 20.6% (a -48.91% decrease from previous year)
  • Twelve month EBIT Margin ending June 29, 2021 was -11.29% (a -57.25% decrease compared to previous quarter)
  • Twelve month trailing EBIT Margin increased by 158.94% year-over-year
Trailing EBIT Margin for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-11.29% -26.41% -21.71% -4.36%
Visit stockrow.com/ANIK for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Margin of Anika Therapeutics Inc.

Most recent EBIT Marginof ANIK including historical data for past 10 years.

Interactive Chart of EBIT Margin of Anika Therapeutics Inc.

Anika Therapeutics Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 24.07% 3.67%
2020 -54.92% -25.01% -31.08% 20.04% -21.71%
2019 16.13% 40.57% 39.17% 22.17% 29.88%
2018 36.21% 32.0% 36.81% -36.83% 20.6%
2017 33.1% 37.78% 52.97% 34.23% 40.32%
2016 44.35% 53.08% 50.67% 48.06% 48.95%
2015 55.24% 55.47% 54.27% 35.46% 51.76%
2014 51.98% 46.64% 57.86% 70.19% 58.19%
2013 49.08% 43.74% 45.12% 32.87% 43.43%
2012 34.47% 18.47% 31.26% 21.33% 27.63%
2011 26.65% 26.1% 22.78% 4.74% 21.56%
2010 16.83% 13.57%

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.